As reported in Langone Health via MedicalXpress, researchers at New York University School of Medicine and GlaxoSmithKline (GSK) are collaborating on an experimental drug that may be effective against a deadly form of pancreatic cancer when used in combination with other immune-boosting therapies. The research results were recently published online in Cancer Cell.

Lead Research/Investigator

George Miller, MD

Source: Medical Xpress

Pin It on Pinterest